Impact of CD70 on aGVHD prevention and treatment
Verma K, Croft W, Margielewska-Davies S, et al. CD70 Identifies Alloreactive T Cells and Represents a Potential Target for Prevention and Treatment of Acute GVHD. Blood Advances. 2024; (doi: 10.1182/bloodadvances.2024012909).
CD70 may be a promising target for preventing acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic stem cell transplantation (allo-HCT) or treating it once it has developed, researchers report. They explain that, in response to allo-HCT, the body develops proinflammatory CD70-positive T cells within the first 2 weeks post-procedure. The highly activated alloreactive cells, which promote proliferation and cytokine secretion, were highly expressed in aGVHD tissue samples. Suppressing CD70 expression on T cells, the scientists note, tempers proliferative and inflammatory cytokine activity, suggesting possible prophylaxis and treatment against the common allo-HCT complication.